A Phase 1 interventional study of Candesartan and Rosuvastatin in Healthy, sponsored by Alvogen Korea. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-03-05.
Sponsored by Alvogen Korea (part of Lotus Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to compare pharmacokinetics after single oral administration of candesartan and rosuvastatin each separately versus coadministration of candesartan and rosuvastatin in healthy male volunteers.
Alvogen Korea is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Candesartan
Drug: Rosuvastatin
AUCτ,ss of candesartan
0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h
Time frame: 22 points
Cmax,ss of candesartan
0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h
Time frame: 22 points
AUCτ,ss of rosuvastatin
0(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h
Time frame: 28 points
Cmax,ss of rosuvastatin
0(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h
Time frame: 28 points
tmax,ss of candesartan
0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h
Time frame: 22 points
CLss/F of candesartan
0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h
Time frame: 22 points
Cmin,ss of candesartan
0h(pre-dose), 1, 2, 3, 4, 5, 6, 7, 8, 12 and 24 h
Time frame: 22 points
tmax,ss of rosuvastatin
0h(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h
Time frame: 28 points
CLss/F of rosuvastatin
0h(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h
Time frame: 28 points
Cmin,ss of rosuvastatin
0h(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12 and 24 h
Time frame: 28 points
The record gives a start of Feb 2014, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Candesartan · Rosuvastatin